Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: A comparative study with diabetic macular oedema (Eye (2009) 23, (1066-1071) DOI: 10.1038/eye.2008.230);Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: A comparative study with diabetic macular oedema

Eye

Volumn 23, Issue 5, 2009, Pages 1066-1071

  Garci Arumi J ^a,b   Fonollosa, A ^a,d   MacI, C ^a   Hernandez, C ^c,d   Martinez Castillo, V ^a   Boixadera, A ^a   Zapata, M A ^a   Simo, R ^c,d  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Ocular Microsurgery Institute   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; BLOOD SAMPLING; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; EPIRETINAL MEMBRANE; FEMALE; HUMAN; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RETINA MACULA EDEMA; RETINA MACULA HOLE; RETINA VEIN OCCLUSION; VITRECTOMY; VITREOUS BODY;

AGED; BIOLOGICAL MARKERS; DIABETIC RETINOPATHY; ERYTHROPOIETIN; FEMALE; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; RETINAL VEIN OCCLUSION; VITREOUS BODY;

EID: 65949093935     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.128     Document Type: Erratum

References (26)

1. Péer J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998; 105: 412-416.
2. Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, Cree IA et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002; 120: 1644-1650.
3. Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003; 110: 1690-1696.
4. Funatsu H, Yamashita H, Nakamura S, Mimura T, Eguchi S, Noma H et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2006; 113: 294-301.
5. Patel JL, Tombran-Tink J, Hykin PG, Gregor ZJ, Cree IA. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: implications for structural differences in macular profiles. Exp Eye Res 2006; 82: 798-806.
6. Ouchi M, West K, Crabb JW, Kinoshita S, Kamei M. Proteomic analysis of vitreous from diabetic macular edema. Exp Eye Res 2005; 81: 176-182.
7. Peters S, Cree IA, Alexander R, Turowski P, Ockrim Z, Patel J et al. Angiopoietin modulation of vascular endothelial growth factor: Effects on retinal endothelial cell permeability. Cytokine 2007; 40: 144-150.
8. Simo R, Lecube A, Sararols L, García-Arumí J, Segura RM, Casamitjana R et al. Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients. Diabetes Care 2002; 25: 2282-2286.
9. Hernandez C, Carrasco E, Casamitjana R, Deulofeu R, Garćia- Arumí J, Simó R. Somatostatin molecular variants in the vitreous fluid: comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects. Diabetes Care 2005; 28: 1941-1947.
10. Simo R, Carrasco E, Fonollosa A, García-Arumí J, Casamitjana R, Hernández C. Deficit of somatostatin in the vitreous fluid of patients with diabetic macular edema. Diabetes Care 2007; 30: 725-727.
11. Watanabe D, Suzuma K, Matsui S. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005; 353: 782-789.
12. Hernandez C, Fonollosa A, Garcia-Ramirez M, Higuera M, Catalán R, Miralles A et al. Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care 2006; 29: 2028-2033.
13. Wilkinson CP, Ferris III FL, Klein RE, Lee PP, Agardh CD, Davis M et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110: 1677-1682.
14. Ciardella AP, Clarkson JG, Guyer DR, Renno RZ, Yannuzzi LA. Central retinal vein occlusion: a primer and review. In: Yannuzzi LA (ed). Retina-Vitreous-Macular. W.B. Saunders: New York, 1999.
15. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005; 24: 493-519.
16. Giardino I, Brownlee M. The biochemical basis of microvascular disease. In: Pickup JC, Williams G (eds). Textbook of diabetes. Blackwell Science: Oxford, 1997; 42.1-42.16.
17. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
18. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and IL-6. Am J Ophthalmol 2005; 140: 256-261.
19. Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2006; 244: 309-315.
20. Antonetti D, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occluding content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes 1998; 47: 1953-1959.
21. Antonetti DA, Lieth E, Barber AJ, Gardner TW. Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin Ophthalmol 1999; 14: 240-248.
22. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999; 14: 223-232.
23. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S et al. Erythropoietin administration protects retinal neurons from acute ischemia reperfusion injury. Proc Natl Acad Sci USA 2002; 99: 10659-10664.
24. Martínez-Estrada OM, Rodríguez-Millán E, González-De Vicente E, Reina M, Vilaró S, Fabre M. Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. Eur J Neurosci 2003; 18: 2538-2544.
25. Uzum G, Sarper Diler A, Bahcekapili N, Ziya Ziylan Y. Erythropoietin prevents the increase in blood brain barrier permeability during pentylenetetrazol-induced seizures. Life Sci 2006; 78: 2571-2576.
26. Friedman EA, L'Esperance FA, Brown CD, Berman DH. Treating azotemia induced anemia with erythropoietin improves diabetic eye disease. Kidney Int 2003; (Suppl 64): S57-S63.